Dako acquires important IP rights in connectivity from System Dynamics

December 21, 2012

Dako, an Agilent Technologies company, has signed an agreement to acquire the intellectual property rights behind connectivity software from California-based software development company System Dynamics, Inc. (SDI). The SDI development team joins Dako and brings new software development competencies to one of the world's leaders in cancer diagnostics.

"The acquisition of the intellectual property rights behind Laboratory Information System (LIS) connectivity software is an important milestone for Dako in our efforts to further strengthen our position and capabilities in LIS connectivity. Moreover, the SDI team will bring important competencies to Dako, ensuring our ability to continue the development of the DakoLink solution to the benefit of our customers in pathology laboratories around the world," says Jacob Thaysen, CVP Dako R&D.

SDI is a longtime business partner and supplier to Dako. Dako and SDI have worked together for 12 years on the design and development of the DakoLink software for use in Dako's Autostainer and Artisan instruments. SDI has also been instrumental in the design of the LIS connectivity product ULISA, which Dako uses to connect the DakoLink solution to LIS systems at more than 150 sites around the world. The agreement provides Dako and Agilent with ownership and control of the intellectual property behind the LIS connectivity software.

Dako and SDI have agreed to keep the purchase price confidential.

Media contact
Lene Christoffersen
Communications
Dako Denmark A/S
Tel. +45 40 74 87 82

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.